RE:RE:Time to get this board working.In contrast, Beckman Coulter Diagnostics' core revenue was down mid-single digits, largely due to significant declines in China resulting from the extensive shutdowns resulting from the COVID-19 pandemic. With fewer patients going to hospitals for non-COVID-19 related treatments or procedures, core lab testing volumes were greatly reduced. However, Joyce said Beckman Coulter has plans for multiple antibody tests, including a high-sensitivity automated IgG serology test expected to launch shortly. He said the company expects to ship 2 million serology tests in May, and 30 million per month by the end of June. The test will run on the global install base of 16,000 immunoassay analyzers, he said.